Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 May;73(9):1074–1079. doi: 10.1038/bjc.1996.207

Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.

C Blomqvist 1, L Risteli 1, J Risteli 1, P Virkkunen 1, S Sarna 1, I Elomaa 1
PMCID: PMC2074399  PMID: 8624266

Abstract

Thirty-six patients with bone metastases included in a trial of supportive calcitonin on the treatment response to systemic therapy were monitored by conventional radiography, conventional indicators of bone metabolism [alkaline phosphatase (AP), osteocalcin (gla), urinary hydroxyproline excretion (OHP), urinary calcium (uCa), serum calcium (sCa)] and collagen metabolites (ICTP, the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen; PICP, the carboxy-terminal propeptide of type I procollagen; and PIIINP the amino-terminal propeptide of type III procollagen). All patients had been on the same systemic treatment for at least 3 months at the start of the trial. There was a positive correlation between the concentrations of ICTP and PICP at baseline (Spearman's rank-order correlation coefficient rs = 0.62). Both ICTP and PICP showed statistically significant correlations to the other markers of bone metabolism (except sCa and uCa) as well as to the number of bone metastases on bone scans. Reduction in ICTP correlated significantly with the treatment response at three months (rs = - 0.57). while PICP showed a borderline negative correlation to therapy response (rs = - 0.37). Of all the biochemical parameters studied the changes in ICTP showed the best correlation with the treatment response. PICP and ICTP changes in patients with progressive disease differed significantly from those in patients with responding and stable metastases, whereas no difference was found between responders and stable patients.

Full text

PDF
1074

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abildgaard N., Nielsen J. L., Heickendorff L. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. Am J Hematol. 1994 Jul;46(3):173–178. doi: 10.1002/ajh.2830460303. [DOI] [PubMed] [Google Scholar]
  2. Bitran J. D., Bekerman C., Desser R. K. The predictive value of serial bone scans in assessing response to chemotherapy in advanced breast cancer. Cancer. 1980 Apr 1;45(7):1562–1568. doi: 10.1002/1097-0142(19800401)45:7<1562::aid-cncr2820450709>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  3. Blomqvist C., Elomaa I., Porkka L., Karonen S. L., Lamberg-Allardt C. Evaluation of salmon calcitonin treatment in bone metastases from breast cancer--a controlled trial. Bone. 1988;9(1):45–51. doi: 10.1016/8756-3282(88)90026-9. [DOI] [PubMed] [Google Scholar]
  4. Blomqvist C., Elomaa I., Virkkunen P., Porkka L., Karonen S. L., Risteli L., Risteli J. The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism. Cancer. 1987 Dec 15;60(12):2907–2912. doi: 10.1002/1097-0142(19871215)60:12<2907::aid-cncr2820601211>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  5. Bonjour J. P., Philippe J., Guelpa G., Bisetti A., Rizzoli R., Jung A., Rosini S., Kanis J. A. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone. 1988;9(3):123–130. doi: 10.1016/8756-3282(88)90001-4. [DOI] [PubMed] [Google Scholar]
  6. Charles P., Mosekilde L., Risteli L., Risteli J., Eriksen E. F. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner. 1994 Feb;24(2):81–94. doi: 10.1016/s0169-6009(08)80147-x. [DOI] [PubMed] [Google Scholar]
  7. Coombes R. C., Dady P., Parsons C., McCready V. R., Ford H. T., Gazet J. C., Powles T. J. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer. 1983 Aug 15;52(4):610–614. doi: 10.1002/1097-0142(19830815)52:4<610::aid-cncr2820520406>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  8. De la Piedra C., Díaz Martín M. A., Díaz Diego E. M., López Gavilanes E., González Parra E., Caramelo C., Rapado A. Serum concentrations of carboxyterminal cross-linked telopeptide of type I collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction. Scand J Clin Lab Invest. 1994 Feb;54(1):11–15. doi: 10.3109/00365519409086504. [DOI] [PubMed] [Google Scholar]
  9. Eberhardt K., Thorbjorn Jensen L., Horslev-Petersen K., Pettersson H., Lorenzen I., Wollheim F. Serum aminoterminal type III procollagen peptide in early rheumatoid arthritis: relation to disease activity and progression of joint damage. Clin Exp Rheumatol. 1990 Jul-Aug;8(4):335–340. [PubMed] [Google Scholar]
  10. Elomaa I., Virkkunen P., Risteli L., Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992 Aug;66(2):337–341. doi: 10.1038/bjc.1992.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Eriksen E. F., Charles P., Melsen F., Mosekilde L., Risteli L., Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res. 1993 Feb;8(2):127–132. doi: 10.1002/jbmr.5650080202. [DOI] [PubMed] [Google Scholar]
  12. Filipponi P., Pedetti M., Beghe F., Giovagnini B., Miam M., Cristallini S. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed. Bone. 1994 May-Jun;15(3):261–267. doi: 10.1016/8756-3282(94)90287-9. [DOI] [PubMed] [Google Scholar]
  13. Frevert E. U., Biester A., Müller M. J., Schmidt-Gayk H., von zur Mühlen A., Brabant G. Markers of bone metabolism during short-term administration of thyroxine in healthy volunteers. Eur J Endocrinol. 1994 Aug;131(2):145–149. doi: 10.1530/eje.0.1310145. [DOI] [PubMed] [Google Scholar]
  14. Hakala M., Risteli L., Manelius J., Nieminen P., Risteli J. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis. 1993 Dec;52(12):866–869. doi: 10.1136/ard.52.12.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hasselbalch H., Junker P., Hørslev-Petersen K., Lisse I., Bentsen K. D. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy. Am J Hematol. 1990 Jan;33(1):18–26. doi: 10.1002/ajh.2830330105. [DOI] [PubMed] [Google Scholar]
  16. Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kauppila A., Puistola U., Risteli J., Risteli L. Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer. Cancer Res. 1989 Apr 1;49(7):1885–1889. [PubMed] [Google Scholar]
  18. Kerstjens H. A., Postma D. S., van Doormaal J. J., van Zanten A. K., Brand P. L., Dekhuijzen P. N., Koëter G. H. Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax. 1994 Jul;49(7):652–656. doi: 10.1136/thx.49.7.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kylmälä T., Tammela T., Risteli L., Risteli J., Taube T., Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer. 1993;29A(6):821–825. doi: 10.1016/s0959-8049(05)80417-4. [DOI] [PubMed] [Google Scholar]
  20. Melkko J., Niemi S., Risteli L., Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990 Jul;36(7):1328–1332. [PubMed] [Google Scholar]
  21. Niemelä O., Risteli J., Blake J. E., Risteli L., Compton K. V., Orrego H. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology. 1990 Jun;98(6):1612–1619. doi: 10.1016/0016-5085(90)91098-q. [DOI] [PubMed] [Google Scholar]
  22. Price P. A., Nishimoto S. K. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2234–2238. doi: 10.1073/pnas.77.4.2234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  24. Robertson J. F., Pearson D., Price M. R., Selby C., Blamey R. W., Howell A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer. 1991 Oct;64(4):757–763. doi: 10.1038/bjc.1991.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sartorio A., Conti A., Monzani M., Morabito F., Faglia G. Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover. J Endocrinol Invest. 1993 Dec;16(11):893–898. doi: 10.1007/BF03348952. [DOI] [PubMed] [Google Scholar]
  26. Taube T., Franssila K., Risteli L., Risteli J., Elomaa I. Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP). Br J Haematol. 1992 Sep;82(1):32–37. doi: 10.1111/j.1365-2141.1992.tb04590.x. [DOI] [PubMed] [Google Scholar]
  27. Taube T., Kylmälä T., Lamberg-Allardt C., Tammela T. L., Elomaa I. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. Eur J Cancer. 1994;30A(6):751–758. doi: 10.1016/0959-8049(94)90287-9. [DOI] [PubMed] [Google Scholar]
  28. Tomás C., Risteli J., Risteli L., Vuori J., Kauppila A. Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma. Obstet Gynecol. 1991 Apr;77(4):566–572. [PubMed] [Google Scholar]
  29. Välimäki M. J., Tähtelä R., Jones J. D., Peterson J. M., Riggs B. L. Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links. Eur J Endocrinol. 1994 Sep;131(3):258–262. doi: 10.1530/eje.0.1310258. [DOI] [PubMed] [Google Scholar]
  30. Wiklund T. A., Blomqvist C. P., Risteli L., Risteli J., Elomaa I. Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas. J Cancer Res Clin Oncol. 1993;119(3):160–164. doi: 10.1007/BF01229531. [DOI] [PubMed] [Google Scholar]
  31. Wiklund T. A., Elomaa I., Blomqvist C. P., Risteli L., Risteli J. Type III collagen metabolism in soft tissue sarcomas. Br J Cancer. 1992 Feb;65(2):193–196. doi: 10.1038/bjc.1992.40. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES